- Home
- DRMA vs TCRT Comparison
DRMA vs TCRT Comparison
Compare DRMA & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- TCRT
- Stock Information
- Founded
- DRMA 2014
- TCRT 1998
- Country
- DRMA United States
- TCRT United States
- Employees
- DRMA N/A
- TCRT N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- TCRT Health Care
- Exchange
- DRMA Nasdaq
- TCRT Nasdaq
- Market Cap
- DRMA 3.6M
- TCRT 3.9M
- IPO Year
- DRMA 2021
- TCRT N/A
- Fundamental
- Price
- DRMA $5.57
- TCRT $2.31
- Analyst Decision
- DRMA Strong Buy
- TCRT
- Analyst Count
- DRMA 1
- TCRT 0
- Target Price
- DRMA $10.00
- TCRT N/A
- AVG Volume (30 Days)
- DRMA 27.3K
- TCRT 340.1K
- Earning Date
- DRMA 08-13-2025
- TCRT 08-14-2025
- Dividend Yield
- DRMA N/A
- TCRT N/A
- EPS Growth
- DRMA N/A
- TCRT N/A
- EPS
- DRMA N/A
- TCRT N/A
- Revenue
- DRMA N/A
- TCRT $6,000.00
- Revenue This Year
- DRMA N/A
- TCRT $5,680,500.00
- Revenue Next Year
- DRMA N/A
- TCRT N/A
- P/E Ratio
- DRMA N/A
- TCRT N/A
- Revenue Growth
- DRMA N/A
- TCRT N/A
- 52 Week Low
- DRMA $5.04
- TCRT $1.31
- 52 Week High
- DRMA $24.90
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- DRMA 45.37
- TCRT 48.15
- Support Level
- DRMA $5.04
- TCRT $2.15
- Resistance Level
- DRMA $5.74
- TCRT $2.39
- Average True Range (ATR)
- DRMA 0.39
- TCRT 0.21
- MACD
- DRMA 0.03
- TCRT 0.08
- Stochastic Oscillator
- DRMA 48.91
- TCRT 78.70
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.